Treatment
Cell clinical trials
We’re tracking 5,550 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT07434947Recruiting
Rehabilitation benefits for advanced lung cancer after treatment
This trial tests whether a rehabilitation program can improve daily function and quality of life for people with advanced non-small cell lung cancer whose disease has been stable for at least 6 months. It aims to find the best way to measure the benefits of physical activity and support, so patients can feel better in their everyday lives.
AnnecyAges 18 years+ - NCT07426484RecruitingPhase 4
Testing cosibelimab for advanced skin cancer in specific patients
This trial tests an immunotherapy drug called cosibelimab for patients with advanced cutaneous squamous cell carcinoma who have either had a kidney transplant or have a blood cancer like lymphoma or myeloma. The goal is to see if it can shrink tumors when surgery or radiation is not an option.
Boston, MassachusettsAges 18 years+ - NCT07429773Recruiting
Immune markers in stubborn pelvic pain
This study looks at the immune system's response in people with chronic pelvic pain that hasn't gotten better with first treatments. By measuring certain immune markers, the researchers hope to better understand why the pain persists and find new ways to help.
Nice, Alpes-MaritimesAges 18–40 - NCT04475952Recruiting
Diagnosing upper digestive problems earlier during routine care
This study aims to learn how to detect problems in the upper digestive tract earlier. People may be asked to help with diagnosis while they are already undergoing routine tests or treatment, which could improve future care.
LondonAges 18–90 - NCT06275230Recruiting
Growing lung stem cells from COPD patients
This trial aims to grow lung stem cells and create mini-lungs (organoids) from the tissue of people with COPD. It may help researchers understand the disease better and develop new treatments.
Beijing, Beijing MunicipalityAges 18–55 - NCT06733051RecruitingPhase 2
Study of Golidocitinib and Benmelstobart for relapsed ENKTL lymphoma
This trial tests a new drug combination for people with a rare type of lymphoma (ENKTL) that has come back or not responded after prior treatment. It aims to see if the combination can help control the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07419841RecruitingPhase 1
A study of CTX-10726 for certain advanced cancers
This trial tests a new drug called CTX-10726 in people with advanced kidney, liver, stomach, or uterine cancer that has not responded to standard treatments. The goal is to see if the drug is safe and tolerable.
Phoenix, ArizonaAges 18 years+ - NCT07424547RecruitingPhase 1
Study of SYS6043 for advanced or metastatic solid tumors
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
Plantation, FloridaAges 18 years+ - NCT07425483RecruitingPhase 1
CAR-NK cell therapy for advanced pancreatic cancer
This trial tests a new treatment using immune cells (CAR-NK cells) to fight pancreatic cancer that has spread or come back. It may be an option if standard treatments have stopped working, were not tolerated, or were refused.
ShanghaiAges 18–75 - NCT07418125Recruiting
Study of tumor cell clusters in high-risk early breast cancer
This trial looks at whether clusters of tumor cells in the blood can give more information about high-risk early breast cancer. It is for people with certain types of breast cancer who are about to start treatment before surgery (neoadjuvant therapy).
LjubljanaAges 18 years+ - NCT07425054RecruitingPhase 2
Chemoradiation with or without immunotherapy for anal cancer
This trial tests whether adding an immunotherapy drug (retifanlimab) to standard chemoradiation improves outcomes for people with locally advanced anal cancer. The treatment is adjusted based on HPV DNA levels in your blood.
Cleveland, OhioAges 18 years+ - NCT07417605Recruiting
Using a new PET scan to tell cancer from inflammation after radiation
This study uses a special PET scan to tell the difference between leftover cancer and inflammation caused by radiation in people treated for head and neck cancer. It may help doctors know if more treatment is needed.
BrestAges 18 years+ - NCT07424222RecruitingPhase 1
Ruxolitinib for a serious immune reaction after CAR T therapy
This trial tests a drug called ruxolitinib for a rare but serious condition called IEC-HS that can happen after CAR T cell treatment. The goal is to see if ruxolitinib can calm this overactive immune response.
Baltimore, MarylandAges 18–99 - NCT05745350RecruitingPhase 2
First treatment for extensive-stage small cell lung cancer
This trial studies how well pembrolizumab, plinabulin, and etoposide plus platinum work as first treatment for extensive-stage small cell lung cancer. It may help some people by boosting the immune response while also attacking cancer with standard chemotherapy.
Wuhan, HubeiAges 18 years+ - NCT06820255RecruitingPhase 4
DNA repair and platinum chemo for advanced bladder cancer
This trial tests how well platinum-based chemotherapy works in people with advanced bladder cancer that has certain DNA repair gene changes. It aims to see if these genetic markers can predict who benefits most from treatment.
RomeAges 18 years+ - NCT07414316RecruitingEarly Phase 1
GK01 cell therapy for advanced lung or esophageal cancer
This trial tests a new cell treatment called GK01 for people with advanced lung cancer or esophageal cancer that has not responded to standard treatments. The study aims to see if this therapy can help shrink tumors or slow the cancer's growth.
NanchangAges 18–75 - NCT07413757Recruiting
Study on factors in choosing lung cancer treatment
This study looks at what doctors and patients consider when deciding on a first-line treatment for advanced lung cancer. It aims to understand how choices are made for people taking a type of targeted therapy.
ChengduAges 18 years+ - NCT07407933RecruitingPhase 1/Phase 2
YL201 with other cancer drugs for advanced solid tumors
This trial tests a new drug, YL201, combined with other cancer treatments for people with a certain type of advanced lung cancer (extensive-stage small cell lung cancer). It may help shrink tumors or slow their growth.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07409428RecruitingPhase 3
Study of HMPL-760 plus R-GemOx for relapsed or refractory DLBCL
This trial tests an experimental drug called HMPL-760 combined with a standard chemo-immunotherapy regimen (R-GemOx) for people whose diffuse large B-cell lymphoma (DLBCL) has come back or stopped responding to treatment. The goal is to see if adding HMPL-760 works better than the standard approach alone.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06809075Recruiting
Stem cell therapy to help highly sensitized patients get a kidney transplant
This trial tests if a special stem cell treatment (using your own stem cells) can reset your immune system so you can accept a kidney from a deceased donor, even if you have very high antibody levels that make it hard to find a match. It's for people who have been waiting a long time and haven't had a transplant offer.
BarcelonaAges 18–65 - NCT07414758RecruitingPhase 3
Golidocitinib vs placebo for PTCL maintenance after first chemo
This trial tests whether a daily pill called golidocitinib can keep your PTCL from coming back after you've had a good response to your first chemotherapy. The study compares the drug to a placebo (a pill with no active medicine) to see if it helps prevent relapse.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07411599RecruitingPhase 1/Phase 2
CAR-NK cell therapy plus cetuximab for belly-spread colorectal cancer
This trial tests a new cell therapy (CAR-NK cells given directly into your belly and a vein) combined with a targeted drug (cetuximab) for colorectal cancer that has spread mainly to the lining of your belly. It aims to see if this treatment can shrink tumors and help people who have run out of standard chemotherapy options.
Houston, TexasAges 18 years+ - NCT07410676RecruitingPhase 1/Phase 2
Donor NK cells with IL-15 and pembrolizumab for advanced solid tumors
This trial tests a new type of cell therapy (natural killer cells) made from a donor, combined with low-dose IL-15 (a protein that helps these cells work) and sometimes with pembrolizumab (Keytruda), for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges Any age - NCT07412041Recruiting
Exercise program for stage II-III lung cancer before surgery
This study tests a personalized exercise program for people with stage II or III non-small cell lung cancer who are about to start cancer treatment before surgery. The goal is to see if exercise can help prepare your body for treatment and recovery.
Boston, MassachusettsAges 18 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,550 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.